Abstract
Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), can lead to acute respiratory distress syndrome (ARDS) and thrombotic disease. Venovenous extracorporeal membrane oxygenation (vv-ECMO) can be a lifesaving intervention in the setting of COVID-19 ARDS, but it comes with significant clotting and bleeding complications. The ideal anticoagulation regimen in COVID-19 ECMO patients is unknown. While continuous infusion heparin is the most common anticoagulant used, the ideal activated partial thromboplastin time (aPTT) range for COVID-19 is undetermined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Vascular Surgery: Venous and Lymphatic Disorders
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
